Intrinsic apoptosis is controlled by the BCL-2 family of proteins but the complexity of intra-family interactions makes it challenging to predict cell fate via standard molecular biology techniques. We discuss BCL-2 family regulation and how to determine
An ongoing phase 1/2 trial (NCT02773030) studied iberdomide in combination with dexamethasone and daratumumab, bortezomib, orcarfilzomibin R/R MM patients who had received three or more prior lines of therapy, including IMiDs (lenalidomide and pomalidomide),proteasomeinhibitors,glucocorticoids, and ant...
6, ATP-binding cassette subfamily C member 6; BTK, Bruton’s tyrosine kinase; GRP78, glucose-regulated protein of 78 kDa; GRP94, glucose-regulated protein of 94 kDa; ICAM-1, intercellular adhesion molecule 1; NAT8L, N-acetylaspartate synthetase; NFAT, nuclear factor of activated T cells....
For patients at high risk of recurrence after transplantation, a variety of new drugs with different action mechanisms such as BTK inhibitors and immunomodulators have been launched into the market. At present, the research on the efficacy and safety of new drugs is also under further exploration...
关键词:B细胞受体信号通路;恶性淋巴瘤;Syk;Btk;PI3K;靶向抑制剂 恶性淋巴瘤原发于淋巴结或结外淋巴组织,是来源于成熟淋巴细胞的恶性肿瘤,主要分为霍奇金淋巴瘤(Hodgkinlymphoma,HL)和非霍奇金淋巴瘤(non Hodgkinlymphoma,NHL)两大类。HL通常多原发于淋巴结,具有特征性的肿瘤细胞Reed Sternberg细胞(里-施细胞)。
431.1999 cysteine residues thusbecome associated membranelipid rafts B-cellSyk phosphorylates BLNK recruitsTec Tecphosphorylates PLC-g LAT-GADS-SOS-Ras-RafCD19 humanimmunodeficiency disease X-linked agammaglobulinemia (XLA), cellsfail mature,results from Btk,while samegene mutated miceleads similar...
facilitatingAKT–PIP 3 interactionandconsequentenzymaticactivation.LINK-A-dependentAKT hyperactivationleadstotumorigenesisandresistancetoAKTinhibitors.GenomicdeletionsoftheLINK-APIP 3 -bindingmotif dramaticallysensitizedbreastcancercellstoAKTinhibitors.Furthermore,meta-analysisshowedthecorrelationbetweenLINK-A expressionand...
For patients at high risk of recurrence after transplantation, a variety of new drugs with different action mechanisms such as BTK inhibitors and immunomodulators have been launched into the market. At present, the research on the efficacy and safety of new drugs is also under further exploration...